Vanin-1 Biomarker Spotlight

Vanin-1 (VAN1) is an anchored protein that catalyzes the hydrolysis of pantetheine to pantothenic acid (vitamin B5) and cyteamine. VAN1 has a broad tissue expression with the highest levels being observed in kidney tubular epithelial cells. The GPI anchor of VAN1 can be cleaved by a yet unknown mechanism, resulting in VAN-1 being shed into the extracellular space.

Vanin-1 plays a pivotal role in oxidative stress and the inflammatory response. However, its relationship with traumatic sepsis remains unknown. In a study aimed to identify whether VAN1 could be used as a biomarker for traumatic sepsis, scientists found there is a significant relationship between plasma VAN1 and sepsis in both the internal test cohort and the external validation cohort. These results contribute to the body of evidence supporting the use of plasma VAN1 in the early prediction of traumatic sepsis.

Learn more about that study here.


Eagle Biosciences offers a comprehensive Vanin-1 ELISA for urine samples.

Vanin-1 ELISA Assay Highlights

  • Optimized for human urine samples
  • Highly SPECIFIC and DEFINED characterized antibodies
  • RELIABLE – rigorously validated
  • QUICK one-step ELISA

We also provide a Vanin-1 Mouse/Rat ELISA Assay Kit that has been validated for mouse or rat serum, plasma, or urine samples.


If you have any questions about this product or our other offerings, contact us here.

PTX3 Biomarker Spotlight
Pentraxins are a superfamily of acute phase reactants characterized by a pentameric structure. Pentraxin 3 (PTX3), is locally produced and released by a variety of cell types including macrophages, neutrophils, myeloid-derived mesangial cells, synovial cells, smooth muscle cells, alveolar epithelium, and glial cells. PTX3 is induced in response to either inflammatory cytokines interleukin-1 β (IL-1 β) and tumor necrosis factor α (TNFα) or the selected associated molecular patterns (PAMPs). PTX3 is elevated in critically ill patients, with a gradient from systematic inflammatory response syndrome to septic shock, and in several other diseases, such as myocardial infarction, rheumatoid arthritis, atherosclerosis, small vessel vasculitis and psoriasis.


Oncologists at Queen Mary’s University whether PTX 3 could be a reliable biomarker for detection of pancreatic ductal adenocarcinoma (PDAC). PDAC is characterized by an intense desmoplastic stroma, laid down by the pancreatic stellate cells (PSC). One of the defining features of PDAC is that there are very few cancer cells. Pancreatic cancer is surprisingly made up of mostly non-cancer cells, which have been co-opted by cancer to build a huge amount of scar tissue or stroma around the cancer, providing a strong defense for the cancer cells. The researchers found that PTX3 is a putative stromally-derived biomarker for PDAC which warrants further testing in prospective, larger, multi-center cohorts and within clinical trials targeting stroma.

To read more about this study, click here.


Related Products

Pentraxin-3 ELISA Assay Kit
High Sensitive CRP ELISA Assay Kit
SAP ELISA Assay Kit

If you have any questions or want to learn more about our offerings, contact us here.

Endostatin Biomarker Spotlight

Endostatin, a 20-kDa C-terminal proteolytic fragment of collagen XVIII, is an endogenous angiogenesis inhibitor localized in the vascular basement membrane in various organs. The biological functions of the endostatin-network involve SPARC, thrombospondin-1, glycosaminoglycans, collagens, and integrins. It is expressed during the progression of renal fibrosis in tubular cells of injured tissue. In renal micro-vascular disease, observed in late stages of patients with chronic kidney disease, increased endostatin levels are possibly the consequence of enhanced extracellular matrix degradation. Thus, it may become an important marker for progressive microvascular renal disease in patients with chronic kidney disease. Endostatin levels in blood are also likely to increase in patients with other microvascular tissue injuries, including atherosclerosis, myocardial- and brain ischemia. In ischemic stroke patients, high endostatin plasma levels predict a worse long-term clinical outcome.


A team of researchers recently demonstrated that serial measurement of endostatin in plasma has useful predictive value for 30-day mortality in Acute Kidney Injury (AKI) patients after major surgery.

Prognostic value of dynamic plasma endostatin for the prediction of mortality in acute kidney injury: A prospective cohort study. Jia HM et al., J Int Med Res. 2020 48(7):300060520940856.. Full Text.


Related Products:
Endostatin ELISA Assay Kit
Endostatin Mouse/Rat ELISA Assay Kit

Sclerostin Biomarker Spotlight

A recent systemic review and meta-analysis of studies with serum amyloid A in patients with COVID-19 published by the International Journal of Infectious Diseases has found high concentrations of serum amyloid A associated with higher COVID-19 severity and mortality. This review analyzed nineteen studies consisting of over five thousand patients with COVID-19. The pooled results showed that serum amyloid A concentrations were significantly higher in those patients with severe disease and non-survivors. This measurement could be useful for risk stratification and clinical monitoring of these patients.

Background


A state of excessive local and systemic inflammation and immune activation are strongly associated with oxidative stress, coagulation abnormalities, and multi-organ dysfunction in patients with coronavirus disease 2019 (COVID-19). While safe and effective vaccines have been developed and are currently being rolled out, effective therapies to mitigate the clinical manifestations of COVID-19, e.g., repurposed antiviral and immunosuppressant agents, remain limited. In this context, the use of biomarkers of disease severity and clinical progression would facilitate the early identification of patients requiring aggressive management and monitoring and assist with the judicious use of healthcare resources. Given the key pathophysiological role of inflammation and immunity in the clinical progress of COVID-19, markers that reflect the activation of these pathways might be particularly useful for risk stratification and effective management.

Serum amyloid A (SAA) genes and proteins are significantly activated during the acute phase response, which comprises a number of phenomena that occur in the presence of inflammation and infection, e.g., increased temperature and hormonal and metabolic alterations. Circulating SAA concentrations, typically low under physiological circumstances (20–50 mg/l), can increase up to 1000-fold within the first 24–48 h of an acute phase response. This is the consequence of increased synthesis in the liver that is triggered by several stimuli, including tumor necrosis factor (TNF), interleukin (IL)-1β, IL-6, and interferon gamma (IFN-γ). SAA, in turn, can activate the complement system and the nucleotide-binding domain leucine-rich repeat-containing family pyrin-domain containing 3 (NLRP3) inflammasome, further increase the synthesis of TNF, IL-1β, and IL-6, and activate other proinflammatory cytokines such as IL-1α and IL-23. Notably, these mediators have been shown to contribute significantly to the onset of the cytokine storm and its adverse clinical consequences in COVID-19. Therefore, it is plausible that the acute increase in SAA concentrations in patients with COVID-19 might not only reflect the presence of an acute phase response, but also herald the development of a cytokine storm and, consequently, multi-organ failure and an increased risk of adverse outcomes.

Two systematic reviews and meta-analyses on a relatively limited number of studies, three and five, respectively, have reported a significant and positive association between SAA concentrations and COVID-19 severity. Following the publication of several additional studies, an updated systematic review and meta-analysis was conducted of the available evidence on the clinical implications of SAA concentrations in patients with COVID-19.

Read the full text here.

Related Products


Human SAA ELISA Assay Kit
Human TNF Alpha ELISA Assay
High Sensitive IFN Gamma ELISA Assay
IL-6 ELISA Assay Kit

If you have any questions about our products contacts us here.

Sclerostin Biomarker Spotlight
Sclerostin is a secreted glycoprotein that functions as a potent inhibitor of Wnt signaling. It acts by binding to the Wnt-coreceptor LRP5/6 thus inhibiting bone formation by regulating osteoblast function and promoting osteoblast apoptosis. Sclerostin is primarily produced by osteocytes. It inhibits the canonical Wnt pathway and thereby osteoblasts. It also stimulates RANKL release by the osteocytes and thereby osteoclast recruitment. Inhibition of sclerostin causes stimulation of bone formation and inhibition of resorption. Read more about sclerostin’s role in bone remodeling here.

Sclerostin levels are altered in response to hormonal stimuli or due to pathophysiological conditions. The concentrations are increased in disorders such as hypoparathyroidism, Paget’s disease, multiple myeloma and in cancer induced bone diseases. Mutations in the SOST gene can cause sclerosteosis and van Buchem disease which are bone dysplasia disorders characterized by progressive skeletal overgrowth. Sclerostin levels are decreased in primary hyperparathyroidism, as well as by the mechanical stimulation of bone.

A mini-review was published in the The Journal of Clinical Endocrinology & Metabolism regarding the effect of sclerostin inhibition on the cardiovascular safety of patients. Read the full text here.


Eagle Biosciences offers a sensitive and reliable assay for the detection of sclerostin in serum and plasma samples.

Advantages of the Sclerostin ELISA Assay Kit

    • High Quality – rigorously validated according to ICH/FDA/EMEA guidelines
    • Low Sample Volume – only 20ul of sample per well
    • Easy – ready to use protocol, standards and controls included

Related Products

Osteoprotegerin ELISA Assay Kit
Free Soluble RANKL ELISA Assay Kit
FGF23 C-Terminal ELISA Assay Kit

If you are looking for any other specific related products, or have any questions about our offerings contact us here.

RANKL and RANK Biomarker Spotlight

Receptor activator of nuclear factor kappa B ligand, RANKL, and its specific receptor RANK, are members of the tumor necrosis factor (TNF) family and are the main stimulatory factor for the formation of mature osteoclasts and are essential for their survival. The major source of RANKL are osteocytes, former osteoblasts that become embedded within the mineralized bone matrix. RANKL and its specific receptor RANK are not only key regulators of bone remodeling but also play an essential role in immunobiology, e.g. lymph node formation, establishment of the thymic microenvironment, mammary gland development during pregnancy, bone metastasis in cancer and sex-hormone, progestin-driven breast cancer, thermoregulation, and finally in the development of type 2 diabetes mellitus.

A recent study has uncovered a new role for RANKL and RANK in bone remodeling. Researchers have found that extracellular vesicles containing RANKL and RANK may have an important role in the long range signaling for bone remodeling. These signaling molecules have the potential to be targeted for therapeutics and also used diagnostically.

Click here to learn more.

Holliday LS, Patel SS, Rody WJ. RANKL and RANK in Extracellular Vesicles: Surprising New Players in Bone Remodeling. Extracell Vesicles Circ Nucleic Acids. 2021; 2:18-28.

Related Products
Free Soluble RANKL ELISA Assay Kit
iLite® RANKL Assay Ready Cells
Osteoprotegerin ELISA Assay Kit
Sclerostin ELISA Assay Kit

Osteoprotegerin Biomarker Spotlight

Osteoprotegerin (ORG) is a secreted protein that affects bone turnover and is implicated in heart and kidney disease. It is a glycoprotein of the TNF receptor superfamily 11b (gene name TNFRSF11B). OPG is synthesized as a monomer of 380 amino acids and is assembled as a homodimer within the cell and then secreted mainly as a disulfide-linked homodimer into the extracellular compartment. OPG is produced by many different tissues and cell types including osteoblasts. OPG is a negative regulator of bone resorption by acting as decoy receptor for RANKL, thus neutralizing its function in osteoclastogenesis. This glycoprotein is also involved in the regulation of vascular calcification. A recent study identifies OPG as an independent risk factor for all-cause mortality in patients after kidney transplantation. 982 prevalent kidney transplant (KT) recipients were followed up for all-cause mortality for 6 years. The researchers observed that each 1 pmol/L higher-serum OPG level was associated with a 49% higher risk of mortality.

Association between serum osteoprotegerin level and mortality in kidney transplant recipients. Gupta V et al., 2021. Transpl Int 19. doi: 10.1111/tri.13847. Epub ahead of print. PMID: 33606319.


Osteoprotegerin Related Products

Osteoprotegerin ELISA Assay Kit
Sclerostin ELISA Assay Kit
Periostin ELISA Assay Kit

Big Endothelin-1 Biomarker Spotlight

Big Endothelin-1 (Big ET-1) is a protein that is mainly produced by vascular endothelial and smooth muscle cells and cardiomyocytes. Big ET-1 is a precursor to Endothelin (ET), the most potent vasoconstrictor known today. The half life of ET is less than one minute, whereas Big ET-1 is cleared more slowly. Big ET-1 can therefore be determined more easily, and has since been identified as a risk factor for a poor prognosis in patients with atrial fibrillation or coronary artery disease. A current study has shown that plasma concentrations of Big ET-1 is a valuable tool for risk stratification in patients with left ventricular non-compaction cardiomyopathy (LVNC). Other studies have also recognized the effectiveness of Big ET-1 as a predictor for numerous cardiovascular diseases.

Prognostic value of plasma big endothelin-1 in left ventricular non-compaction cardiomyopathy. Fan P, et al. Heart 2020;0:1–6. doi:10.1136/heartjnl-2020-317059

Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients. Li XY et al., 2020. J Geriatr Cardiol 28;17(7):427-433.

Plasma big endothelin-1 predicts new-onset atrial fibrillation after surgical septal myectomy in patients with hypertrophic cardiomyopathy. Song C et al., 2019. BMC Cardiovasc Disord 22;19(1):122.

Plasma level of big endothelin-1 predicts the prognosis in patients with hypertrophic cardiomyopathy. Wang Y et al., 2017. Int J Cardiol 15;243:283-289.


Related Products:

Big Endothelin-1 ELISA Assay Kit.
NT-proANP ELISA Assay Kit
NT-proCNP ELISA Assay Kit
NT-proBNP ELISA
BNP Fragment ELISA Assay Kit

If you have any questions regarding our Big Endothelin-1 ELISA Assay Kit or any other kits in the Cardiovascular Assay line, contact us here.

Glycoprotein 2 (GP2), the pancreatic major zymogen granule membrane glycoprotein, is has been recognized in recent years as the major antigenic target of Crohn’s Disease specific anti-pancreatic antibodies. Anti-Glycoprotein (Anti-GP2) IgA and IgG antibodies have been studied as critical biomarkers for the detection of a number of diseases, including Crohn disease, ulcerative colitis, pancreatitis, and inflammatory bowel disease.

Pancreatitis GP2 ELISA

Eagle partner Generic Assays offers a highly sensitive ELISA for the detection of acute pancreatitis-specific GP2 in serum.

Read more about related products by following these links:
Pancreatitis GP2
Sharpening the CD/UC discrimination: Antibodies to Glycoprotein 2
Pancreatic GP2-Specific Auto-Antibodies are Markers of Crohn’s Disease

GP2 Antibody Assays can be found here:

Anti-GP2 (Glycoprotein 2) IgA ELISA Assay Kit
Anti-GP2 (Glycoprotein 2) IgG ELISA Assay Kit

Contact us for more information about our GP2 related assay kits.

References

Lael Werner, Daniela Paclik, Christina Fritz, Dirk Reinhold, Dirk Roggenbuck, Andreas Sturm. Identification of Pancreatic Glycoprotein 2 as an Endogenous Immunomodulator of Innate and Adaptive Immune Responses. The Journal of Immunology. September 15, 2012, 189 (6) 2774-2783; DOI: 10.4049/jimmunol.1103190. https://doi.org/10.4049/jimmunol.1103190

Bogdanos, Dimitrios P.; Roggenbuck, Dirk; Reinhold, Dirk; Wex, Thomas; Pavlidis, Polychronis; von Arnim, Ulrike; Malfertheiner, Peter; Forbes, Alastair; Conrad, Karsten; Laass, Martin W. (2012) Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease. BMC Gastroenterology. 102 (12) 1; DOI: 10.1186/1471-230X-12-102. https://doi.org/10.1186/1471-230X-12-102

Roggenbuck, D., Goihl, A., Hanack, K., et al. (2016). Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2. Clinical Chemistry and Laboratory Medicine (CCLM), 55(6), pp. 854-864. Retrieved 23 Sep. 2019, from doi:10.1515/cclm-2016-0797.

Valentina Somma, Hani Ababneh, Ahmad Ababneh, et al., “The Novel Crohn’s Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease,” Gastroenterology Research and Practice, vol. 2013, Article ID 683824, 7 pages, 2013. https://doi.org/10.1155/2013/683824.

Shulan Zhang, Ziyan Wu, Jing Luo, Xuefeng Ding, Chaojun Hu, Ping Li, Chuiwen Deng, Fengchun Zhang, Jiaming Qian, Yongzhe Li. (2015). Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients with Crohn Disease. Medicine, 94 (42). doi: 10.1097/MD.0000000000001654.

Noggin is a secreted homodimeric glycoprotein that is involved in the development of many body tissues, including nerve tissue, muscles, and bones. Noggin is crucial during embryogenesis and is involved in the regulation of several developmental processes, including neural tube formation, cardiomycyte growth, skeletal development, and joint formation. Noggin is highly conserved in vertebrates, and is found in certain areas of the central nervous system, lungs, skeletal muscles, and skin of adults.

Why is it important?

Research has shown that noggin plays a role in learning, cognition, bone development, and neural tube function, as well as nervous system, somite and skeletal development. A lack of noggin during embryo development can lead to stunted bone growth, missing skeletal elements, or failure to develop articulating joints. Mutations of the noggin gene can cause joint fusions, multiple synostosis, proximal symphalangism and other deformities or syndromes.

In adult patients, increased levels of noggin in plasma have been linked to obesity.

NOGGIN has also been linked to:
Bone Tumors
Ankylosing Spondylitis
Non Alcoholic Fatty Liver Disease (NAFLD)
Pulmonary Arterial Hypertension (PAH)

Eagle Biosciences offers a highly sensitive Metal Enhanced Direct Sandwich Fluorescence Immunoassay to test for Noggin.
FluoBolt-Noggin Fluorescence Immunoassay

Contact us for more information about our Noggin Assay.